Resume-CV 1_May_2015

1
Charles M. Beasley, Jr., M.D.
8161 Beech Knoll
Indianapolis, IN 46256-2107
+1.317.435.5330 Mobile
charlesmbeasleyjr@MSN.com
First-tier, executive level experience in the design, conduct, analysis, and successful submission
of multiple Phase II-IV development programs. Additional work with select Phase I studies in
various areas especially cardiac electrophysiology assessment. Extensive experience in the
domain of drug safety evaluation in response to high-profile challengesto the safety profiles of
several drugs. Published widely in the scientific literature while in industry, gaining the respect of
the academic community as exemplified by being elected to the highly competitive and
prestigious American College of Neuropsychopharmacology. Training and research in computer
science and statistics facilitate accurate and efficient collaboration with data scientists and
statisticians, enhancing quality in progressing from study protocols to submissions and scientific
manuscripts.
PROFESSIONAL POSITIONS
Eli Lilly and Company July 1987-30/Apr/2015
Global Patient Safety (GPS) April 2004-30/Apr/2015
Distinguished Lilly Scholar (Vice-Presidential level) Oct. 2004-30/Apr/2015
Distinguished Lilly Fellow April 2004-Oct. 2004
 Consulted for individual projects to the Vice-President GPS and Medical Director GPS
 Engaged in activities relevant to the assessment of drug safety of my choosing
 Designed comprehensive assessments incorporated work ranging from in vitro research, through
toxicology, Phase 1 studies, clinical trials (Phase II-IV), post-marketing surveillance, and large
database pharmacoepidemiology studies tailored to address topics of special relevance for select
drugs (additional detail confidential)
 Performed in-depth due diligence from a safety perspective for potential collaboration molecules
 Internal committee participation
o Global Product Labeling Committee: committee making final decisions regarding contents of
Core Data Sheets (CDSs) for drugs
o Hepatic Safety Advisory Committee
o Cardiovascular Safety Advisory Committee (CvSAC)
o ECG Sub-Committee (of CvSAC)
o Psychobehavioral Advisory Committee
o Laboratory Data Analysis Working Group
o Adverse Events Analysis Working Group
o Standards Control Board: group assuring that data collection / case report forms are
consistent with CFAST/CDISC standards
 Participated in design, analysis, and interpretation of Thorough QT (TQT) studies
 Developed revised and consistent reference limits for numerical hemodynamic parameters and
quantitative ECG findings
 Revised the set of possible qualitative ECG findings used during the interpretation of qualitative ECG
observations to minimize ambiguity and inconsistency across ECGs

2
 Contributed to revision of interpretive standards (i.e., diagnostic criteria) for the set of possible
qualitative ECG findings and documented academic literature supporting those interpretive standards
 Designed the analytical methods resulting in summary statistical tables for qualitative ECG data
 Supervised extensive research on reference limits for standard safety laboratory analytes optimized
for use in analysis of outliers in randomized clinical trials, in contrast to limits optimized for individual
patient care (research ongoing)
 Authored the clinical sections of the external CFAST/CDISC Therapeutic Area for TQT Studies
 Served as an author for a cross-industry PhUSE whitepaper recommending standard analyses for
TQT studies
 Collaborated with statisticians to design the standardized analyses and output for the Summaries of
Clinical Safety / Integrated Summaries of Safety for NDAs / European submissions / internal major
safety update reviews
 Developed internal standardized methods for use of data from multiple clinical trials in the
development of the list of adverse reactions for incorporation into CDSs
 Worked hands-on with most teams bringing molecules forward for initial submission and therefore
CDS with organization of studies, their analysis, and interpretation with regard to identifying Adverse
Reactions
 Authored / co-authored several academic manuscripts in the areas of QT, assessment methods in
drug safety, safety topics for specific drugs
 Designed a Phase I study to sensitively assess weight gain potential for a new molecular entity
Neuroscience Business Unit Jan. 2003-April 2004
Distinguished Lilly Fellow
 Consulted to the President of the Business Unit
 Was available for consultation to other therapeutic area business units on matters of both efficacy
(experimental design) and safety (methods of assessment, interpretation)
 Designed comprehensive assessments that incorporated work ranging from in vitro research, through
toxicology, Phase 1 studies, clinical trials (Phase II-IV), post-marketing surveillance, and large
database phrmacoepidemiology studies tailored to address topics of special relevance for select
drugs (additional detail confidential)
 Consulted to the program phase development teams developing metabotropic glutamate receptor
platform compounds as antipsychotics and a selective norepinephrine uptake inhibitor as an
adjunctive antidepressant in depression non-responsive to a serotonin uptake inhibitor
Tadalafil (Cialis®) Product Team July 2001-Jan. 2003
Distinguished Lilly Fellow and Medical Director
 Supervised the design and execution of all activities required to achieve regulatory approval in the EU
and the US for tadalafil for the treatment of erectile dysfunction subsequent to the initial US NDA and
EU submission documents
 Planned analyses to address multiple and distinct questions from both US and European regulators
regarding tadalafil submission as well as a multiple component plan to address a topic of special
interest to European regulators (additional detail confidential)
 Designed additional Phase I studies to support the initial indication for tadalafil
o Length of activity study to document activity for at least 36 hours
o Interaction with nitrates study to demonstrate magnitude of effect under controlled and safe
circumstances

3
o Interaction with alcohol study to demonstrate magnitude of any additive hypotensive effect
o TQT study
 Designed and initiated Phase IV studies intended to support the commercialization of tadalafil in the
treatment of erectile dysfunction
 Outlined potential development programs for tadalafil in the treatment of additional indications,
including diabetic gastroparesis, benign prostatic hypertrophy, and pulmonary hypertension
 Directly supervised and managed 4 physicians in support of the activities listed above
Olanzapine (Zyprexa®) Product Team Jan. 1995-July 2001
Distinguished Lilly Fellow July 1999-July 2001
Medical Advisor Jan. 1995-July 1999
 Following US and European approval of olanzapine for schizophrenia / psychosis
o Consulted on additional olanzapine indication development programs: various phases of
bipolar disorder, dementia / manifestations of dementia and alternative formulation
development programs: rapidly dissolving tablet, rapid acting intramuscular formulation
o Designed and executed the study to demonstrate maintenance / long-term antipsychotic
efficacy of olanzapine
o Supervision and assessment of any and all safety topics of special relevance regarding
olanzapine that included developed multiple in-depth safety reports for safety topics of
special relevance for olanzapine and interacted with US and international regulatory
authorities with regard to these topics with successful outcomes (additional detail
confidential)
o Participated in design of glycemic clamp studies to assess impact of olanzapine on glycemic
control
o Interface with Japanese investigators and direct planning and writing of Japanese olanzapine
submission (Giyo) for schizophrenia
o Management of all clinical aspects of initial Japanese development program for olanzapine
o Consulted to marketing on post-approval activities for olanzapine
o Transitional team leader for metabotropic glutamate receptor platform
o Designed and executed a successful Phase III study for a metabotropic glutamate receptor
compound after 5 failed Phase II studies
 Prior to US and European approval for schizophrenia / psychosis
o Supervised the analysis and writing of US and European regulatory submission documents
for olanzapine that resulted in simultaneous approval in 13 months following submissions
o Consulted to marketing on preapproval activities for olanzapine
Neuroscience / Psychopharmacology Division of Clinical Investigation July 1987-Jan. 1995
Senior Clinical Research Physician March 1992-Jan. 1995
Research Physician Aug. 1989-March 1992
Associate Clinical Research Physician July 1987-Aug.1989
 Olanzapine Phase
o Oversaw all medical aspects of design and implementation of the 5 Phase II-III studies for
olanzapine in the treatment of psychosis / schizophrenia
 Fluoxetine (Prozac®) and tomoxetine Phase

4
o Had overall medical responsibility for fluoxetine including efficacy, safety, advancement of
scientific understanding and marketing support, including design and execution of 10 Phase
IV studies
o Had overall medical responsibility for Phase III development tomoxetine as an antidepressant
(program terminated and molecule developed with generic name atomoxetine [Strattera®] for
attention deficit hyperactivity disorder), including design and execution of 3 Phase II studies
o Initiated a program for publication of multiple never-published fluoxetine study results as well
as post-hoc data mining from fluoxetine studies to clarify important clinical and scientific
aspects of the activity of fluoxetine in order to increase medical knowledge of fluoxetine,
provide marketing support, and increase personal academic stature
o Successfully lead the data analysis effort in 1990-1991 to clarify and rebut, if warranted, the
assertion that fluoxetine induces suicidal ideation of unique clinical characteristics and distinct
from other antidepressants
o Conducted in-depth review and evaluation of the problem of placebo response in
antidepressant trials
o Completed routine regulatory safety review documents for fluoxetine and prepared special
reports to address safety topics of special relevance for fluoxetine
o Provided marketing support and review for fluoxetine
Group Health Associates, Cincinnati, OH May 1987-June 1987
Physician, Psychiatric Disorders
Eating Disorders Center, Cincinnati Medical Center July 1985-March 1987
Consultant, Medical Support for Bulimia Clinical Trial, Psychiatry Dept.
Affective Disorders Center, University Of Cincinnati Medical Center June 1985-May1986
Physician, Sub-Investigator for Antidepressant Clinical Trial, Psychiatry Dept.
Neuropsychology Laboratory, Yale University School of Medicine July 1978-Aug.1979
Associate In Research, Database And Software Designer, Neurology Dept.
Dept. Psychology, Yale University June 1977-July 1978
Research Programmer, Software Developer in Machine Learning Artificial
Intelligence Research
ACADEMIC APPOINTMENTS
Voluntary Assistant Professor Jan. 1989-June 1996
Department of Psychiatry, University of Cincinnati
POSTGRADUATE TRAINING
University of Cincinnati 1984-87
Department of Psychiatry; PGY-II-IV, General Psychiatry residency
Yale University 1983-84
Department of Psychiatry; PGY-I Flexible intern at the Hospital of St. Raphael
EDUCATION
M.D., University of Kentucky College of Medicine 1983
B.A., Psychology Yale University 1977

5
CERTIFICATION AND LICENSURE
National Board of Medical Examiners Diplomate 1984
American Board of Psychiatry and Neurology Diplomate (Psychiatry) 1988
Medical License: Ohio; Indiana; Maine
AWARDS AND HONORS
Sandoz Pharmacology Award 2nd year medical school
Promoted with distinction 2nd and 3rd years medical school
Elected to AOA and AOA president 3rd year medical school
AMA-ERF Rock Sleyster Memorial Scholar 4th year medical school
Cornelia B. Wilbur Psychiatry Departmental Award 4th year medical school
Neurology Departmental Award 4th year medical school
Graduated medical school with high distinction 1983
Laughlin Fellow American College of Psychiatrists, 1987
1st place, Maurice Levine Essay Award Cincinnati Psychiatric Society, 1987
4th Year Resident’s Award Department of Psychiatry, University of Cincinnati, 1987
Resident’s Research Award Department of Psychiatry, University of Cincinnati, 1987
Founder’s Day Resident Award Paper Ohio Psychiatric Association, 1987
PROFESSIONAL SOCIETY FELLOWSHIPS
American Psychiatric Association
American College of Psychiatrists
American College of Neuropsychopharmacology
Royal College of Physicians of the United Kingdom
PROFESSIONAL SOCIETY MEMBERSHIPS
Indiana Psychiatric Society
American Federation for Clinical Research
American Society of Clinical Psychopharmacology
EDITORIAL BOARD MEMBERSHIPS
Section Editor, Psychopharmacology The Open Pharmacology Journal
Editorial Board Current Psychopharmacology
Editorial Board World Journal of Psychiatry
Editorial Board The Scientific World Journal
Editorial Board ISRN Psychiatry
Editorial Board Journal of Cardiovascular Disorders
REVIEWER
Journal of Clinical Psychopharmacology
Archives of General Psychiatry
Psychological Bulletin
Psychological Medicine
Biological Psychiatry
Neuropsychiatric Diseases and Treatment
Progress in Nero-Psychopharmacology & Biological Psychiatry
American Journal of Psychiatry

6
OTHER PROFESSIONAL ACTIVITIES
Co-chairperson History Committee American College of Neuropsychopharmacology 2008-2010
Co-chairperson PMA Education & Research Institute Pharmacology Training Series: Central Nervous
System Pharmacology Washington, D.C. Sep 29-30, 1993
Co-chairperson Paper Session 41: Comorbidity in affective disorders American Psychiatric Association
Annual Meeting Montreal, Canada May 12, 1988
PATENTS ISSUED
5605897 2-Methyl-Thieno-Benzodiazepine (Olanzapine)
5817656 Method for Treating Mental Disorders (Olanzapine)
5817657 Method for Treating Psychoactive Substance Disorders (Olanzapine)
5776928 Method for Treating Dyskinesia (Olanzapine)
6071902 Method for Treating Excessive Aggression (Olanzapine)
6159963 Method for Treating Substance Abuse (Olanzapine)
6274636 Method of Treating Tic Disorder (Olanzapine)
6506746 Method for Treating Cognitive Dysfunction (Olanzapine)
BOOK CHAPTERS
1. Beasley C, Grundy S, Gannon K, Berg P
Overview of the safety of olanzapine
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
Olanzapine (Zyprexa): A Novel Antipsychotic
Philadelphia: Lippincott Williams & Wilkins, 2000
2. Tran P. Sutton V, Beasley C, Tollefson G
Efficacy of olanzapine
In Tran P, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (Eds.)
Olanzapine (Zyprexa): A Novel Antipsychotic
Philadelphia: Lippincott Williams & Wilkins, 2000
3. Anderson J, Kline P, Beasley C
A general learning theory and its application to schema abstraction
In Bower G (Ed.)
The Psychology of Learning and Motivation, Vol 13.
New York: Academic Press, 1979
Complex learning processes
In Snow R, Federico P & Montague W (Eds.)
Aptitude, Learning, and Instruction, Vol 2: Cognitive Process Analysis of Learning and Problem
Solving
Hillsdale, NJ: Lawrence Erlbaum and Associates, 1980

7
ARTICLES
1. Crowe B, Brueckner A, Beasley C, Kulkarni P
Current practices, challenges, and statistical issues with product safety labeling
Statistics in Biopharmaceutical Research 5:180-193; 2013
2. Loghin C, Haber H, Beasley CM, Kothare PA, Kauffman L, April J, jin L, Allen AJ, Mitchell MI
Effect of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers
Br J Clin Pharmacol 75:549-564; 2013
3. Beasley C, Benson C, Xia J, Young S, Haber H, Mitchell M, Loghin C
Systematic decrements in QTc between the first and second day of contiguous daily ECG
recordings under controlled conditions
PACE 34:1116-1127; 2011
4. Millen BA, Campbell GM, Beasley CM
Weight changes over time in adults treated with oral or depot formulations of olanzapine:
a pooled analysis of 86 clinical trials
J Psychopharmacol 25:639-645; 2011
5. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K,
Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley
B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan
ND, Sheehan DV
Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target
for for drug development: a brief report
J Clin Psychiatry 71:1040-1046; 2010
6. Meyer RE, Salzman C, YoingstromEA, ClaytonPJ, Goodwin FK, Mann JJ, Alphs LD, Broich K,
Goodman WK, Greden JF, Meltzer HY, Normand SL, Posner K, Shaffer D, Oquendo MA, Stanley
B, Trivedi MH, Turecki G, Beasley CM, Beautrais AL, Bridge JA, Brown GK, Revicki DA, Ryan
ND, Sheehan DV
Suicidality and risk of suicide – definition, drug safety concerns, and a necessary target
for for drug development: a consensus statement
J Clin Psychiatry 71:pe1-pe21; 2010
7. Lipkovich I, Jacobson JG, Caldwell C, Hoffman VP, Kryzhanovskaya L, Beasley CM
Early predictors of weight gain risk during treatmentwith olanzapine: analysis of pooled
data from 58 clinical trials
Psychopharm Bull 42:23-39; 2009

8
8. Beasley CM, Dmitrienko A, Mitchell MI
Design and analysis considerations for thorough QT studies employing conventional (10
s, 12-lead) ECG recordings
Expert Rev Clin Pharmacol 1:815-839; 2008
9. Beasley C, Ball S, Nilsson M, et al
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data
sources from placebo-controlled trials
J Clin Psychopharmacol 27:682-686; 2007
10. Tauscher-Wisniewski S, Disch, Plewes J, Ball SG, Beasley CM
Evaluating suicidality as an adverse event in clinical trials of fluoxetine treatment for
indications other than major depressive disorder
Psychol Med 37:1-9; 2007
11. Beasley CM, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM,
All-cause treatment discontinuation in schizophrenia during treatmrnt with olanzapine
relative to other antipsychotics: an integrated analysis
12. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F,
Strong RE, Rosenbaum JF, Fava M
Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of
fluoxetine for major depressive episodes
Psychother Psychosom 76:40-46; 2007
13. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis
RH
Early symptomatic worsening during treatment with fluoxetine in major depressive
disorder: prevalence and implications
J Clin Psych 68:52-57; 2007
14. Crumb WJ, Ekins S, Darazan RD, Wikel JH, Wrighton SA, Carlson C, Beasley CM
Effects of Antipsychotic Drugs on Ito, INa, Isus, IK1, and hERG: QT prolongation, atructure
activity relationship and network analysis
Pharmacol Res 23:1133-1143; 2006
15. Beasley CM, Sutton VK, Taylor CC, Sethuraman G, Dossenbach M, Naber D
Is quality of life among minimally symptomatic patients with schizophrenia better
following withdrawal or continuation of antipsychotic treatment?

9
16. Carrier S, Brock GB, Pommerville PJ, Shin J, Anglin G, Whitaker JS, Beasley CM
Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile
dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial
J Sexual Med 2:685-698; 2005
17. Beasley CM, Mitchell MI, Dmitrienko AA, Emmick JT, Shen W, Costigan TM, Bedding AW, Turick
MA, Bakhtyari A, Warner MR, Ruskin JN, Cantilena LR, Kloner RA
The combined use of ibutilide as an active control with intensive ECG sampling and signal
averaging as a sensitive method to assess the effects of taalafil on the human QT interval
J Am Coll Cardiol 46:678-687; 2005
18. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, Murphy AM, Beasley
CM, Hague JA, Ahuja S
Tadalafil improved erectile function at 24 and 36 hours after dosing: US trial
J of Andrology 26:310-318; 2005
19. Sarazan RD, Crumb WJ, Beasley CM, Emmick JT, Ferguson KM, Strnat CA, Sausen PJ
Absence of clinically important HERG channel blockade by three compounds that inhibit
phosphodiesterase 5 – sildenafil, tadalafil, and vardenafil
E J Pharmacology 502:163-167; 2004
20. Von Keitz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T, Lockhart D, Beasley C, Emmick J
A multicenter, randomized, double-blind, crossover study to evaluate patient preference
between tadalafil and sildenafil
Eu Urology 45:499-507; 2004
21. Beasley C, Sutton V, Hamilton S, Walker D, Dossenbach M, Taylor C, Alaka K, Bykowski D,
Tollefson G
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of
psychotic relapse
22. Helstrom WJG, Overstreet JW, Yu A, Saikali K, Shen W, Beasley, CM, Watkins VS
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones
J Urology 170:887-891; 2003
23. Carlson CD, Cavazzoni PA, Berg PH, Wei H, Beasley CM, Kane JM
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients
with schizophrenia during olanzapine clinical trials: comparisons with placebo,
haloperidol, risperidone, or clozapine

10
24. Lindborg S, Beasley C, Alaka K, Taylor C
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in
acutely agitated patients
Psychiatry Res 119:113-123; 2003
25. Quitkin F, Petkova E, McGrath P, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M,
Rosenbaum J, Reimherr F, Fawcett J, ChenY, Klein D
When should a trial of fluoxetine for major depression be declared failed?
Am J Psychiatry 160:734-740; 2003
26. Inada T, Beasley C, Tanaka Y, Walker D
Extrapyramidal symptom profiles assessed with DIEPSS: comparison with western scales
in the clinical double-blind studies of schizophrenic patients treated with either olanzapine
or haloperidol
Intl Clin Psychopharmacol 18:39-48; 2003
27. Sowell M, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg H, Breier, Breier A, Beasley C,
Dananberg J
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects
treated with olanzapine, risperidone, or olanzapine. J
Clin Endocrinology and Metab 87:2918-2923; 2002
28. Meehan K, Wang H, David S, Nisivoccia J, Jones B, Beasley C, Feldman P, Mintzer J, Beckett L,
Breier A
Comparison of rapidly acting intramuscular olanzapine, lorazxepam, and placebo: a
double-blind, randomized study in acutely agitated patients with dementia
Neuropsychopharmacology 26:494-504; 2002
29. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment
J Affect Diord 68:243-249; 2002
30. Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, Bernauer B, Kinon B, Baker
R, Hau D, Roth H, Dossenbach M, Kaiser C, Beasley C, Holcombe J, Effron M, Breier A
A current review of olanzapine’ssafety in the geriatric patient: from pre-clinical
pharmacology to clinical data
Int J Geriatr Psychiatry 16:S33-S61; 2001
31. Brunswick D, Amsterdeam J, Fawcett J, Quitkin F, Reimherr, Rosenbaum J, Beasley C
Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy

11
32. Czekalla J, Beasley C, Dellva M, Berg P, Grundy S
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia
and related psychosis
33. Czekalla J, Kollack-Walker S, Beasley C
Cardiac Safety Parameters of Olanzapine: comparison with other atypical and typical
antipsychotics
J Clin Psychiatry 62:suppl 2:35-40; 2001
34. Czekalla J, Beasley CM, Ditmann RW, Helsberg K, Kollack-Walker S
Kardiale verträglichkeit unter nueroleptika: vergleichende übersicht zu Qtc-parametern
und assoziierten effekten unter olanzapin und anderen atypischen sowie typischen
antipsychotika
Nervenheilkunde 20:194-201; 2001
35. Perry P, Lund B, Sanger T, Beasley C
Olanzapine plasma concentrations and clinical response: acute phase results of the North
American olanzapine trial
36. Beasley C, Koke S, Nilsson M, Gonzales J
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major
depressive disorder: an updated meta-analysis
Clin Ther 22:1319-1330; 2000
37. Voss S, Sanger T, Beasley C
Hematologic reference ranges in a population of patients with schizophrenia
J Clin Psychopharmacol 20:653-657, 2000
38. Beasley C, Nilsson M, Koke S, Gonzales J
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of
major depression: a meta-analysis of the 20-mg/day dose
39. McGrath P, Stewart J, Petkova E, Quitkin F, Amsterdam J, Fawcett J, Reimherr F, Rosenbaum J,
Beasley C
Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major
Depression

12
40. Michelson D, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Zajecka J, Sundell K, Kim Y,
Beasley C
Changes in Weight During a 1-Year Trial of Fluoxetine
Am J Psychiatry 156:1170-1176; 1999
41. Revicki D, Genduso L, Hamilton S, Ganoczy D, Beasley C
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic
disorders: Quality of life and clinical outcomes of a randomized clinical trial
Qual Life Res 8:417-426; 1999
42. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C
Fluoxetine efficacy in menopausal women with and without estrogen replacement
J Affect Disord 55:11-17; 1999
43. Callaghan J, Bergstrom R, Ptak L, Beasley C
Olanzapine: pharmacokinetic and pharmacodynamic profile
Clin Pharmacokinet 37:177-193; 1999
44. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Beasley C
Blood pressure changes during short-term fluoxetine treatment
45. Zajecka J, Amsterdam J, Quitkin F, Reimberr F, Rosenbaum J, Tamura R, Sundell K, Michelson
D, Beasley C
Changes in adverse events reported by patients during 6 months of fluoxetine therapy
46. Beasley C, Dellva M, Tamura R, Morgenstern H, Glazer W, Ferguson K, Tollefson G
Randomized double-blind comparison of the incidence of tardive dyskinesia in patients
with schizophrenia during long-term treatment with olanzapine or haloperidol
Br J Psychiatry 174:23-30; 1999
47. Tran P, Tollefson G, Sanger T, Lu Y, Berg P, Beasley C
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and
long-term therapy
Br J Psychiatry 174:15-22; 1999
48. Sanger T, Lieberman J, Tohen M, Grundy S, Beasley C, Tollefson G
Olanzapine versus haloperidol treatment in first episode psychosis
Am J Psychiatry 156:79-87; 1999
49. Amsterdam J, Garcia-Espana F, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Schweizer E,
Beasley C
Efficacy and Safety of Fluoxetine in Treating Bipolar II Major Depressive Episode

13
50. Reimherr F, Amsterdam J, Qutikin F, Rosenbaum J, Fava M, Zajecka J, Beasley C, Michelson D,
Roback P, Sundell K
Optimal length of continuation therapy in depression: a prospective assessment during
long-term fluoxetine treatment
Am J Psychiatry 155:1247-1253; 1998
51. Beasley C
Olanzapine: recent clinical findings and increased patient benefits
Japanese J Clin Psychopharmacol 1:759-765; 1998
52. Tollefson G, Sanger T, Beasley C, Tran P
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus
haloperidol or placebo on anxious and depressive symptoms accompanying
schizophrenia
Biol Psychiatry 43:803-810; 1998
53. Tran P, Dellva M, Tollefson G, Wentley A, Beasley C
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and
related psychoses
Br J Psychiatry 172:499-505; 1998
54. Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley
C
Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study
55. Stewart J, Quitkin F, McGrath P, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J,
Beasley C, Roback P
Use of pattern analysis to predict differential relapse of remitted patients with major
depression during 1 year of treatment with fluoxetine or placebo
Arch Gen Psychiatry 55:334-343; 1998
56. Hamilton S, Revicki D, Genduso L, Beasley C
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North
American double-blind Trial
Neuropsychopharmacology 18:41-49; 1998
57. Perry P, Sanger T, Beasley C
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic
patients

14
58. Dellva M, Tran P, Tollefson G, Wentley A, Beasley C
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance
treatment of schizophrenia
Psychiatric Services 48:1571-1577; 1997
59. Goldstein D, Hamilton S, Masica D, Beasley C
Fluoxetine in Medically Stable, Depressed Geriatric Patients: Effects on Weight
60. Crawford A, Beasley C, Tollefson G
The acute and long-term effect of olanzapine compared with placebo and haloperidol on
serum prolactin concentrations
Schizophrenia Res 26:41-54; 1997
61. Tran P, Hamilton S, Kuntz A, Potvin J, Andersen S, Beasley C, Tollefson G
Double-blind comparison of olanzapine versus risperidone in the treatment of
schizophrenia and other psychotic disorders
62. Tollefson G, Beasley C, Tamura R, Tran P, Potvin J
Blind, controlled, long-term study of the comparative incidence of treatment-emergent
tardive dyskinesia with olanzapine or haloperidol
Am J Psychiatry 154:1248-1254; 1997
63. Beasley C, Tollefson G, Tran P
Safety of olanzapine
J Clin Psychiatry 58:Suppl 10:13-17; 1997
64. Beasley C, Tollefson G, Tran P
Efficacy of olanzapine: an overview of pivotal clinical trials
J Clin Psychiatry 58:Suppl 10:7-12; 1997
65. Blumenfield M, Levy N, Spinowitz B, Charytan C, Beasley C, Dubey A, Solomon R, Todd R,
Goodman A, Bergstrom R
Fluoxetine in depressed patients on dialysis
Intl J Psychiatry in Medicine 27:71-80; 1997
66. Beasley C, Hamilton S, Crawford A, Dellva M, Tollefson G, Tran P, Blin O, Beuzen J
Olanzapine versus haloperidol: acute phase results of the international double-blind
olanzapine trial
Euro Neuropsychopharmacol 7:125-137; 1997

15
67. Amsterdam J, Fawcett J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Hornig-Rohan M,
Beasley C
Fluoxetine and norfluoxetine plasma concentrations in major depre ssion: a multicenter
study
Am J Psychiatry 154:963-969; 1997
68. Tran P, Dellva M, Tollefson G, Beasley C, Potvin J, Kiesler G
Extrapyramidal Symptoms and tolerability of olanzapine versus haloperidol in the acute
treatment of schizophrenia
69. Tollefson G, Beasley C, Tran P, Street J, Kruger J, Tamura R, Graffeo K, Thieme M
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and
schizophreniform disorders: results of an international collaborative trial
Am J Psychiatry 154:457-465; 1997
70. Beasley C
Safety of olanzapine
J Clin Psychiatry Monograph 15:2:19-21; 1997
71. Beasley C
Efficacy of olanzapine
J Clin Psychiatry Monograph 15:2:17-19; 1997
72. Levy N, Blumenfield M, Beasley C, Dubey A, Solomon R, Todd R, Goodman A, Bergstrom R
Fluoxetine in depressed patients with renal failure and in depressed patients with normal
kidney function
Gen Hosp Psychiatry 18:8-13; 1996
73. Beasley C, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Psychopharmacology 124:159-167; 1996
74. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S
Olanzapine versus placebo and haloperidol: acute phase results of the North American
double-blind olanzapine trial
Neuropsychopharmacol 14:111-123; 1996
75. Tollefson G, Rampey A, Beasley C, Enas G, Potvin J
Absence of a relationship between adverse events and suicidality during
pharmacotherapy for depression

16
76. Tollefson G, Fawcett J, Winokur G, Beasley C, Potvin J, Faries D, Rampey A, Sayler M
Evaluation of suicidality during pharmacologic treatment of mood and non-mood
disorders
Ann Clin Psychiatry 5:209-224; 1993
77. Beasley C, Holman S, Potvin J
Fluoxetine compared with imipramine in the treatment of inpatient depression : a
multicenter trial
78. Beasley C, Sayler M, Potvin J
Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial
79. Heiligenstein J, Beasley C, Potvin J
Fluoxetine not associated with increased aggression in controlled clinical trials
80. Beasley C, Potvin J
Fluoxetine: activating and sedating effects
81. Bergstrom R, Beasley C, Levy N, Blumenfield M, Lemberger L
A review of the effects of renal and hepatic disease on the pharmacokinetics, renal
tolerance, and their risk-benefit profile of fluoxetine
Intl Clin Psychopharmacology 8:261-266; 1993
82. Beasley C, Masica D, Heiligenstein J, Wheadon D, Zerbe R
Possible monoamine oxidase inhibitor – serotonin uptake inhibitor interaction: fluoxetine
clinical data and preclinical findings
83. Goldstein D, Rampey A, Potvin J, Masica D, Beasley C
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for
weight reduction
84. Heiligenstien J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D
Fluoxetine not associated with increased violence or aggression in controlled clinical
trials
85. Beasley C, Sayler M, Weiss A, Potvin J
Fluoxetine: activating and sedating effects at multiple fixed doses

17
86. Wheadon D, Rampey A, Thompson V, Potvin J, Masica D, Beasley C
Lack of association between fluoxetine and suicidality in bulimia nervosa
87. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstein J, Thompson V,
Murphy D, Masica D
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression
Intl Clin Psychopharmacol 6:Suppl 6:53-75; 1992
88. Beasley C, Masica D, Potvin J
Fluoxetine: a review of receptor and functional effects and their clinical implications
Psychopharmacology 107:1-10; 1992
89. Beasley C, Potvin J, Masica D, Wheadon D, Dornseif B, Genduso L
Fluoxetine: no association with suicidality in obsessive-compulsive disorder
J Affective Disorders 24:1-10; 1992
90. Beasley C, Dornseif B, Bosomworth J, Sayler M, Rampey A, Heiligenstien J, Thompson V,
Murphy D, Masica D
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression
BMJ 303:685-692; 1991
91. Beasley C, Poltz J, Dornseif B, Bosomworth J, Sayler M
Fluoxetine versus trazodone: efficacy and activating-sedating effects
92. Beasley C, Sayler M, Bosomworth J, Wernicke J
High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded
depression
93. Usher R, Beasley C, Bosomworth J
Efficacy and safety of morning versus evening fluoxetine administration
94. Beasley C, Sayler M, Cunningham G, Weiss A, Masica D
Fluoxetine in tricyclic refractory major depressive disorder
J Affective Disorders 20:193-200; 1990
95. Beasley C, Bosomworth J, Wernicke J
Fluoxetine: relationships among dose, response, adverse events, and plasma
concentrations in the treatment of depression
Psychopharm Bull 26:18-24; 1990

18
96. McCombs J, Nichol M, Stimmel G, Sclar D, Beasley C, Gross L
The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in
a Medicaid population
J Clin Psychiatry 51:6, suppl:60-69; 1990
97. Beasley C, Magnusson M, Garver D
TSH response to TRH and haloperidol response latency in psychoses
Biol Psychiatry 24:423-31; 1988
LETTERS
1. Beasley C
Response (letter).
Aust N Z J Psychiatry 33:12-122; 1999.
2. Perry PJ, Sanger T, Beasley CM
Plasma olanzapine and clinical response (Response letter).
J Clin Psychopharmacol 19:193-194; 1999.
3. Beasley C
Response (letter).
Br J Psychiatry 175:391-392; 1999.
4. Beasley C
Response (letter).
CNS Drugs 9:513-515; 1998.
5. Beasley C
Response (letter).
Neuropsychopharmacol 16:89-90; 1997.
6. Beasley C
Fluoxetine-Dopaminergic Interaction Data (letter).
J Clin Psychiatry 55:77-78; 1994.
7. Masica D, Beasley C, Kotsanos J, Potvin J
Trend in suicide rates since fluoxetine introduction (letter).
Am J Pub Health 82:1295; 1992.
8. Beasley C
Reply (letter).
J Clin Psychopharmacol 12:220-221; 1992.
9. Beasley C
Fluoxetine and suicide (letter).
BMJ 303:1200; 1991.

19
10. Fuller R, Beasley C
Fluoxetine: mechanism of action (letter).
J Am Acad Child Adolesc Psychiatry 30:849-850; 1991.
11. Beasley C
Correction to ‘Fluoxetine Overdose: A Case Report’ (letter).
J Anal Tox 14:63; 1990.
ABSTRACTS AND POSTERS (SELECTED)
1. Camporeale A, Beasley C, Tanaka Y, D’Souza D, Upadhyaya H
Changes in blood pressure and heart rate associated with atomoxetine treatment in
attention-deficit/hyperactivity disorder
Euro Neuropsychopharmacol 22:429-430; 2012.
2. Gatz JL, Jamal HH, Plewes JM, Case MG, Beasley CM
Treatment-resistant major depressive disorder: comparison of acute (2-week) safety
endpoints after switching treatment from other antidepressants to olanzapine/fluoxetine
combination therapy
Annual Meeting of the American College of Neuropsychopharmacology. Holywood, FL, Dec. 7,
2009.
3. Beasley CM, Disch D, Chen W, Witte M, Acharya N, Perahia D, Nilsson, M, Perlis R
Potential risk factors for development of treatment-emergent suicidal ideation in the
duloxetine placebo-controlled major depressive disorder database
Annual Meeting of the American College of Neuropsychopharmacology. Boca Raton,
FL, Dec. 12, 2007.
4. Beasley CM, Disch D, Prabhakar V, Desiah D, Tamura R, Perlis R
Potential predictive factors for development of treatment-emergent suicidal ideation in the
fluoxetine placebo-controlled major depressive disorder database
Neuropsychopharmacol 31:S1:100-101; 2006.
5. Acharya NV, Rosen AS, Polzer JP, DSouza DN, Perahia DG, Cavazzoni PA, Beasley CM,
Baldessarini RJ
Duloxetine: meta-analysis of suicidal behaviors and thoughts in clinical trials for major
depressive disorder
Neuropsychopharmacol 30:S1:S97; 2005.
6. Beasley CM, Sutton VK, Taylor C, Sethuraman G, Dossenbach M, Naber D, Pickar D
Does maintenance treatment with atypical antipsychotics worsen quality of life among
stable patients with schizophrenia?

20
7. Beasley C, Stauffer V, Liu-Seifert H, Rock S, Mitchell C, Dunayevich E, Davis J, Breier A
Overall treatment effectiveness as measured by time continuing on antipsychotic therapy
8. Beasley C, Acharya N, Polzer J, Nilsson M, Rosen A, Cavazzoni P
Nomenclature for suicide-related thoughts and behaviors
American Academy of Child and Adolescent Psychiatry. Washington, DC, Oct. 21, 2004.
9. Beasley CM, Sowell MO, Carlson C, Mukhnopadhyay N, Dannanberg j, Henry R, Breier A,
Cavazzoni P
Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in
healthy volunteers treated with olanzapine, risperidone or placebo
Schizophrenia Res 60:309, 2003.
10. Beasley C, Sowell M, Henry R, Carlson C, Mukhopadhyay N, Dananberg J, Cavazzoni P, Breier
A
Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in
healthy volunteers treated with olanzapine, risperidone, or placebo
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec. 11,
2002.
11. Czekalla J, Beasley C, David S, Berg P, Stauffer V, Boylan C
Cardiac conduction in femalesunder intramuscular (IM) and oral olanzapine from
schizophrenia clinical trials ECGs
Euro Neuropsychopharmacol 12:S3:S291-292; 2002.
12. Tohen M, David RS, Beasley CM, Alaka K
QT intervals: IM olanzapine treatment in acutely agitated patients
European Psychiatry 17:105; 2002.
13. Beasley C, Sowell M, Cavazzoni P, Breier A, Steinberg H, Dananberg J
Assessment of insulin secretory responses using the hyperglycemic clamp in normal
subjects treated with olanzapine, risperidone, or placebo
Annual Meeting of the American College of Neuropsychopharmacology
Kona, HA, Dec. 10, 2001.
14. Beasley CM, Hamilton SH, Dossenbach M
Relapse prevention with olanzapine
Schizophrenia Res 41:196-197; 2000.
15. Czekalla J, Dellva MA, Berg PH, Grundy SL, Beasley CM
Cardiac safety profile of olanzapine based on preclinical and clinical ECG data
Schizophrenia Res 41:195; 2000.

21
16. Beasley C, Berg P, Dananberg J, Kwong K, Taylor C, Breier A
Incidence and rate of treatment-emergent potential impaired glucose tolerance and
potential diabetes with olanzapine compared to other antipsychotic agents and placebo
2000.
17. Jones B, Wang H, David S, Nisivoccia J, Beasley C, Feldman P, Meehan K
A double-blind, placebo controlled study of short-acting intramuscular olanzapine and
lorazepam in acutely agitated patients with dementia
2000.
18. Beasley CM, Hamilton SH, Dossenbach M
Relapse prevention with olanzapine
Euro Neuropsychopharmacol 10:304; 2000.
19. Crumb W, Beasley C, Thornton A, Breier A
Cardiac ion channel blocking profile of olanzapine and other antipsychotics
Annual Meeting of the American College of Neuropsychopharmacology. Alcapulco, Mexico, Dec.
13, 1999.
20. Tran PV, Basson BR, Kennedy JS, Beasley CM, Bymaster FP, Tollefson GD
The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone
treatment in patients with schizophrenia spectrum psychosis
21. Schmidt M, Michelson D, Beasley CM, Kopp J, Koke S
Long term treatment outcomes of highly anxious depressed patients: evidence from a 52-
week trial with fluoxetine
22. Basson B, Kennedy J, Tran P, Beasley C, Bymaster F, Tollefson G
The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone
treatment in patients with schizophrenia spectrum psychosis
Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto
Rico, PR, Dec. 15, 1998.
23. Beuzen J, Birkett M, Kiesler G, Tollefson G, Wood A, Beasley C
Olanzapine vs clozapine: an international double-blind study in treatment resistant
schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, PR, Dec.
16, 1998.

22
24. Tamura R, Michelson D, Sundell K, Beasley C
Adverse event profiles associated with long-term fluoxetine treatment
American Psychiatric Association Annual Meeting. Toronto, Canada, June 3, 1998.
25. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H
The differential risk of tardive dyskinesia with olanzapine
American Psychiatric Association Annual Meeting. Toronto, Canada, June 2, 1998.
26. Wright P, Tollefson G, Beasley C, Tamura R, Tran P, Potvin J
A blinded, controlled, long-term study of the comparative incidence of treatment-emergent
tardive dyskinesia with olanzapine or haloperidol
27. Jones B, Crawford A, Beasley C, Tollefson G
serum prolactin concentration
28. Tamura R, Beasley C, Dellva M, Glazer W, Morgenstern H, Tollefson G
What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?
29. Reams S, Sanger T, Beasley C
Olanzapine in the treatment of elderly patients with schizophrenia and related psychotic
disorders
Schizophrenia Res 29:151-152, 1998.
30. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G
Olanzapine in the treatment of schizoaffective disorder
31. Beasley CM, Sayler ME, Kiesler GM, Potvin JH, Sanger TM, Tollefson GD
The influence of pharmacotherapy on self-directed and externally-directed aggression in
schizophrenia
32. Tollefson G, Sanger T, Beasley C
A blinded trial on the course and relationship of depressive symptoms in schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 8, 1997.
33. Tran P, Tollefson G, Beasley C, Crawford A
From molecule to marketplace: profile of the atypical antipsychotic olanzapine
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10,
1997.

23
34. Beasley C, Tollefson G, Dellva M, Tamura R, Glazer W, Morgenstern H
What is the differential risk of tardive dyskinesia with the atypical antipsychotic
olanzapine?
Annual meeting of the American College of Neuropsychopharmacology. Kona, HA, Dec. 10,
1997.
35. Dellva M, Tamura R, Glazer W, Morgenstern H, Beasley C
What is the differential risk of tardive dyskinesia with the atypical antipsychotic
olanzapine?
serum prolactin concentration
37. Crawford A, Gomez J, Beasley C, Tollefson G
Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center
international trial
38. Conley R, Tamminga C, Beasley C
Olanzapine vs. Chlorpromazine in treatment resistant schizophrenia
Annual meeting of the American College of Neuropsychopharmacology. San Juan, PR; Dec. 12,
1996.
39. Tran P, Dellva M, Rampey V, Tollefson G, Beasley C
Long-term continuation therapy with the novel antipsychotic olanzapine: a review of the
clinical experience
40. Kuntz A, Tran P, Dellva M, Sanger T, Beasley C, Tollefson G
Acute phase efficacy and safety of olanzapine: a review
41. Dellva M, Satterlee W, Tran P, Beasley C, Greaney M, Tollefson G
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute
treatment
42. Lu Y, Sanger T, Beasley C, Tran P, Tollefson G
Olanzapine in the treatment of schizoaffective disorder
European Neuropsychopharmacology 6:106; 1996.

24
The course of primary and secondary negative symptoms in a placebo- and comparator-
controlled trial of the atypical antipsychotic olanzapine
44. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S
Olanzapine versus placebo, results of the United States double-blind olanzapine trial
45. Quicken FM, Stewart JW, McGrath PJ, Beasley C
Pattern analysis predicts relapse on fluoxetine and placebo during continuation
46. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S,Van Ostrand R, Paul S
Acute and long-term results of the North American double-blind olanzapine trial
Euro Neuropsychopharmacol 6:59; 1996
47. Martin C, Genduso L, Revicki D, Hamilton S, Tran P, Beasley C
Quality of life outcomes of olanzapine, a new atypical antipsychotic agent
48. Tollefson GD, Beasley CM, Tran PV, Tamura RN, Sanger TM, Wood A, Beuzen JN
Olanzapine versus haloperidol: results of the multi-center international trial
49. Tran P, Dellva M, Street J, Beasley C, Tollefson G, Kiesler G
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in acute
treatments
World Congress of Psychiatry. Madrid, Spain; Aug. 26, 1996.
50. Dellva M, Tran P, Beasley C, Cousins L, Krueger J, Tollefson G
Clinical experience with long-term continuation treatment with olanzapine
World Congress of Psychiatry. Madrid, Spain; Aug. 25, 1996.
51. Beasley C
Olanzapine safety overview
World Congress of Psychiatry. Madrid, Spain, Aug. 23, 1996.
The course of primary and secondary negative symptoms in a controlled trial with
olanzapine
CINP. Melbourne, Australia, June 26, 1996.
53. Tran P, Beasley C, Tollefson G, Dellva M, Hamilton S, Van Ostrand R, Paul S

25
54. Tran P, Beasley C, Street J, Tamura R, Dellva M, Graffeo K, Kruger J, Tollefson G
Olanzapine versus haloperidol: acute results of the multi-center international trail
55. Beasley C, Tran P, Beuzen J, Tamura R, Dellva M, Bailey J, Kruger J, Tollefson G
Olanzapine versus haloperidol: long-term results of the international trial
56. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, Bradley P, Paul S
Olanzapine versus placebo, results of the United States double-blind olanzapine trial
57. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J,
Wood A, Graffeo K, Meltzer H
Olanzapine in the treatment of schizophrenia and other psychotic disorders
NCDEU Annual Meeting. Boca Raton, FL, May 24, 1996.
58. Satterlee W, Beasley C, Sanger T, Tollefson G
a clinical update on olanzapine: atypical antipsychotic
NCDEU Annual Meeting. Boca Raton, FL, May 23, 1996.
Olanzapine: impact of an atypical antipsychotic candidate on prolactin release
American Psychiatric Association Annual Meeting. New York, NY, May 9, 1996.
60. Patel B, Kurtz D, Callaghan J, Beasley C, Bergstrom R
Effect of smoking and gender on population pharmacokinetics of olanzapine
61. Tran P, Dellva M, Beasley C, Satterlee W, Cousins L, Tollefson G
Clinical experience with long-term continuation treatment with olanzapine
62. Satterlee W, Beasley C, Tran P, Tamura R, Krueger J, Tollefson G
Olanzapine versus haloperidol: results of a large multicenter international trial
The course of primary and secondary negative symptoms in a controlled trial with
olanzapine
64. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T
Olanzapine: molecule to drug candidate

26
65. Beasley C, Tran P, Tamura R, Tollefson G
Olanzapine versus haloperidol: results of the multi-center international trial
1995.
66. Tran P, Beasley C, Dellva M, Cousins L, Gusman S, Tollefson G
Long-term efficacy and safety of olanzapine
Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR Dec. 13,
1995.
67. Tran P, Beasley C, Crawford A, Hamilton S, Tollefson G
Belgian College of Neuropsychopharmacology and Biological Psychiatry (BCNBP). Kortenberg,
Belgium, Dec. 1, 1995.
68. Tollefson G, Beasley C, Tran P, Sanger T
Olanzapine: an exciting atypical antipsychotic-the clinical experience
European College of Neuropsychopharmacology Annual Meeting. Venice, Italy, Oct. 1, 1995.
69. Dittmann R, Beasley C, Geuppert M, Muhlenbacher
Clinical efficacy and safety of olanzapine: results from a double blind-multinational trial
Pharmacopsychiatry 28:172; 1995.
70. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T, Hamilton S
Clinical efficacy and safety of increasing doses of olanzapine, a new “atypical”
antipsychotic agent
CINP Regional Conference. Vienna, Austria and Prague, Czech Republic, June 10, 1995.
71. Beuzen J, Tran P, Beasley C, Tollefson G, Sanger T
Clinical efficacy and safety of olanzapine, a new “atypical” antipsychotic agent
72. Beuzen J, Beasley C, Tran P, Sanger T, Paul S, Tollefson G
Additional clinical experience with olanzapine, an “atypical” antipsychotic
73. Tran P, Beasley C, Tollefson G, Crawford A, Paul S
Olanzapine: an update on recent clinical studies
NCDEU Annual Meeting. Orlando, FL, June 1, 1995.
74. Tollefson G, Beasley C, Tran P, Satterlee W, Lu Y, Mesters P, Gomez J, Dittman R, Beuzen J,
Graffeo K, Kolling C, Paul S
NCDEU Annual Meeting. Orlando, FL, May 31, 1995.

27
75. Tollefson G, Beasley C, Tran P, Sanger T
The next generation of antipsychotics
American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995.
Additional clinical experience with olanzapine, an atypical antipsychotic
American Psychiatric Association Annual Meeting. Miami, FL, May 24, 1995
77. Tran P, Beasley C, Tollefson G, Blin O, Hamilton S, Wharton I, Cousins L, Kiesler G, Greaney M,
Gussman S
Clinical efficacy and safety of increasing doses of olanzapine: a new “atypical”
antipsychotic agent
78. Tran P, Beasley C, Tollefson G, Satterlee W, Small J, Besancon G, Naber D, Sanger T, Bailey J,
Graffeo K, Wood A, Meltzer H
79. Beasley C, Tran P, Tollefson G, Satterlee W, Crawford A, Wharton I, Luttman C, Voegele T
Long-term efficacy and safety of olanzapine: a novel “atypical” antipsychotic agent
80. Beasley C, Tollefson G, Tran P, Satterlee W
Olanzapine: a potential atypical antipsychotic
81. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T, Satterlee W
Olanzapine: a promising “atypical” antipsychotic agent
82. Saterlee W, Beasley C, Sanger T, Tollefson G
Additional clinical experienceswith olanzapine an “atypical” antipsychotic
83. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G
Olanzapine a new “atypical” antipsychotic
84. Tollefson G, Sanger T, Beasley C, Tran P
Is there a relationship between EPSE and efficacy: fact or fiction
Scientific Council of the International Academy for Biomedical and Drug Research. Florence,
Italy, Mar. 11, 1995.

28
85. Beuzen J, Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G
Additional clinical experience with olanzapine, an “Atypical” Antipsychotic
Critical Issues in the Treatment of Schizophrenia Workshop. Florence, Italy, Mar. 11, 1995.
86. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S
Euro Neuopsychopharmacol 5:347-348; 1995.
87. Amsterdam JD, Hornig-Rohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW,
Beasley CM
Fluoxetine and norfluoxetine levels in major depression
Biological Psychiatry 37:606; 1995.
88. Tollefson GD, Beasley CM, Tran PV, Sanger T
Olanzapine: a novel antipsychotic with broad spectrum profile
Biological Psychiatry 35:746-747; 1994.
89. Tran P, Beasley C, Satterlee W
Sanger T, Holman S, Tollefson G
Olanzapine: a potential novel antipsychotic agent
1994.
1994.
91. Beasley C, Satterlee W, Sanger T, Paul S, Tollefson G
Additional clinical experienceswith olanzapine an “atypical” antipsychotic
1994.
92. Satterlee W, Beasley C, Sanger T, Tran P, Paul S, Tollefson G
Olanzapine a new “atypical” antipsychotic
Annual Meeting of the American College of Neuropsychopharmacology. San Juan. Dec. 14,
1994.
93. Tran P, Beasley C, Tollefson G, Holman S
Clinical efficacy and safety of olanzapine: a novel antipsychotic agent
European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18,
1994.

29
European College of Neuropsychopharmacology Annual Meeting. Jerusalem, Israel, Oct. 18,
1994.
95. Wood A, Beasley C, Tollefson G, Tran P
Efficacy of olanzapine in the positive and negative symptoms of schizophrenia
96. Tran P, Beasley C, Tollefson G, Beuzen J, Holman S, Sanger T
Plan Asian-Pacific Conference on Mental Health. Beijing, China, Oct. 12, 1994.
97. Tran P, Beasley C, Tollefson G, Satterlee W, Sanger T
Clinical efficacy and safety of olanzapine: a potential atypical antipsychotic age nt
Pan Asian-Pacific Conference on Mental Health. Beijing, China, Oct 12, 1994.
A clinical update on olanzapine, an “atypical” antipsychotic
Institute on Hospital and Community Psychiatry Annual Meeting. San Diego, CA, Oct. 3, 1994.
99. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P, Sanger T
Preclinical and clinical observations of olanzapine (a new antipsychotic agent)
Schizophrenia 1994: 3rd International Conference. Vancouver, Canada, Aug. 23, 1994.
100. Tran P, Beasley C, Tollefson G, Sanger T, Satterlee W
Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent
Neuropsychopharmacol 10:3S, Part 2:267S; 1994.
101. Beasley C, Tollefson G, Moore N, Tye N
Olanzapine: the new “atypical” antipsychotic agent
Neuropsychopharmacol 10:3S, Part 1:536S; 1994.
102. Satterlee W, Beasley C, Tollefson G, Moore N, Tran P
Preclinical and clinical observations of olanzapine (a new antipsychotic)
NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.
103. Rosenbaum J, Fava M, Quitkin F, Fawcett J, Amsterdam J, Reimherr F, Beasley C
Time to remission of depression with acute fluoxetine treatment
NCDEU Annual Meeting. Marco Island, FL, June 2, 1994.
Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent
Canadian College of Neuropsychopharmacology Annual Meeting. Montreal, Canada, May 31,
1994.

30
Clinical efficacy and safety of olanzapine: a new atypical Antipsychotic agent
American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.
106. Beasley C, Tollefson G, Tran P, Satterlee W
Olanzapine: a potential atypical antipsychotic
American Psychiatric Association Annual Meeting. Philadelphia, PA, May 24, 1994.
107. Beasley C, Tollefson G, Moore N
Olanzapine: a new “atypical” antipsychotic agent
Eighth Triannual Congress of the Israel Psychiatric Association. Tiberias, Israel, May 3, 1994.
108. Rosenbaum J, Quitkin F, Fava M, Amsterdam J, Fawcett J, Zajecka J, Lebegue B,
Reimherr F, Beasley C
Fluoxetine vs. Placebo: long-term treatment of MDD
Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15,
1993.
109. Beasley C, Tollefson G, Tye N, Moore N
Olanzapine: a potential “atypical” antipsychotic agent
Annual Meeting of the American College of Neuropsychopharmacology. Honolulu, HA, Dec. 15,
1993.
110. Sayler M, Pande A, Beasley C, Tollefson G
Antidepressant efficacy and severity of depression
American Psychiatric Association Annual Meeting. San Francisco, CA, May 26, 1993.
111. Tye N, Moore N, Rees G, Sanger G, Calligaro D, Beasley C
Preclinical pharmacology of olanzapine: a novel ‘atypical’ antipsychotic agent
Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.
112. Beasley C, Montgomery S, Tye N
Olanzapine: an open-label study in schizophrenia
Second International Conference on Schizophrenia. Vancouver, Canada, July 21, 1992.
113. Beasley C, Sayler M
Fluoxetine: activating and sedating effects at multiple fixed doses
CINP. Nice, France, June 29, 1992.
114. Bergstrom R, Beasley C, Levy N, Dubey A, Blumenfield M, Goodman A, Solomon R
Fluoxetine pharmacokinetics after daily doses of 20 mg fluoxetine in patients with severely
impaired renal function
Pharmaceutical Research 8:S294; 1991.

31
115. Heiligenstein J, Coccaro E, Potvin J, Beasley C, Dornseif B, Masica D
Fluoxetine not associated with violent behavior in controlled clinical trials
Clinical Research 39:768A; 1991.
116. Beasley C, Faries D, Sayler M, Potvin J
Fluoxetine not associated with suicidality in international controlled clinical trials in
depression
Clinical Research 39:767A; 1991.
117. McDermott B, Beasley C, Kelly K, Hirschowitz J, Garver D
Confounds of neuroendocrine challenge tests
American Psychiatric Association Annual Meeting. Montreal, Canada, May 10, 1988.
118. Garver D, Beasley C, Kelly K, Magnusson M, Johnson C, Chopra Y
Antipsychotic response latencies: separate diseases
American Psychiatric Association Annual Meeting. Montreal, Canada, May 9, 1988.
119. Garver D, Beasley C, Sautter F, Chopra Y
Early antipsychotic response with neuroleptics and dopamine psychosis
1987.
120. Sautter F, McDermott B, Beasley C
Short-term outcome of schizophreniform disorder
American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.
121. Beasley C, Garver D
Growth hormone response and neuroleptic response in neuroleptic naïve patients
American Psychiatric Association Annual Meeting. Chicago, IL, May 12, 1987.
122. Beasley C, Magnusson M, Garver D
TSH response to TRH and haloperidol response latency in psychoses
Society for Biological Psychiatry Annual Meeting. Chicago, IL, May 7, 1987.
GRANT REPORTS
A theory of the acquisition of cognitive skills
Technical Report 77-1. Yale University, 1978
Complex learning processes
Technical Report 78-1. Yale University, 1978

32
INVITED PRESENTATIONS (SELECTED)
1. Beasley C
A tale of two profiles: the hemodynamic effects of atomoxetine under clinical observation
vs. intensive monitoring
Cardiac Safety Research Consortium – Pediatric Cardiovascular Safey Drug and Medical Device
Development Thinktank. Silver Spring, MD, Dec. 10, 2010.
2. Beasley C
How to characterize the QT effect in the targeted patient population when a TQT study is
positive
DIA Conference: Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and
Bleeding. Arlington, VA, Apr. 12, 2009.
3. Beasley C
Regulatory, procedural, and statistical considerations in the thorough QT study: the
complexity of the design of a thorough QT study
World Pharmaceutical Congress. Philadelphia, PA, May 12, 2008.
4. Beasley C
Conduct & Design of a TQT Study
Keynote address. QT and Drug Development. London, England, Oct. 24, 2007.
5. Beasley C
Effective strategies for designing thorough QT studies
eXlpharma webinar. Sept. 27, 2007.
6. Beasley C
Why we need improved preclinical predictors and human biomarkers for torsades de
pointe
Keynote presentation, Cardiac Safety. World Pharmaceutical Congress. Philadelphia, PA, June
12, 2007.
7. Beasley C
Is 36,000 ECGs overkill?
DIA Conference – Challenges and Practical Aspects of Assessing Clinical QT Prolongation /
Proarrhythmia Risk and Implications for the Critical Pathway. Washington, DC, May 9, 2006.
8. Beasley C
Do we need a new ear, a new purse, or both? OR What do we need to more effectively and
efficiently confirm the absence of risk of torsades?
Cardiac Safety and Critical Pathway Initiative Regulatory Think-Tank. Bethesda, MD, Oct. 11,
2005.
9. Beasley C
Drug development from the industry perspective: challengesand opportunities
A Workshop on Clinical Trials in Psychopharmacology. New York, NY, Apr. 12, 2005.
10. Beasley C
Olanzapine
British Association for Psychopharmacology Regional Meeting. Guilford, England, Oct. 10, 1997.
11. Beasley C
Olanzapine: atypical antipsychotic
American Society of Clinical Pharmacology and Therapeutics Annual Meeting. Orlando, FL, Mar.
21, 1996.

33
12. Beasley C
Olanzapine clinical development: molecule to drug candidate
NCDEU Annual Meeting. Orlando, FL, June 1, 1995.
13. Beasley C
Clinical trial design in depression and anxiety
PMA Education and Research Institute Course Drug Development in Depression and Anxiety.
Boston, MA, Mar. 15, 1994.
14. Beasley C
Atypical antipsychotics: What are they?
Grand Rounds, Cleveland Clinic. Cleveland, OH, Nov. 4, 1993.
15. Beasley C
Olanzapine
International Congress on Schizophrenia Research. Colorado Springs, CO, Apr. 20, 1993.
16. Beasley C
Fluoxetine in tricyclic refractory major depressive disorder
Second International Conference on Refractory Depression. Amsterdam, The Netherlands, June
26, 1992.
17. Beasley C
Fluoxetine: significance of plasma concentrations and impact on psychomotor
performance
1992 Annual Lectureship in Forensic Toxicology. Annual meeting of the American Academy of
Forensic Sciences. New Orleans, LA, Feb. 21, 1992.
18. Beasley C, Farries D
Fluoxetine: worldwide suicidality data
Annual Meeting of the American College of Neuropsychopharmacology (Study Group). San
Juan, PR, Dec. 11, 1991.
19. Beasley C, Farries D
Strategies to lower placebo response rates in depressed patients in antidepressant trials
Annual Meeting of the American College of Neuropsychopharmacology (Study Group). San Juan,
PR, Dec. 9, 1991.
20. Beasley C, Dornseif B
Placebo response in depression: associated variables?
Annual Meeting of the American College of Neuropsychopharmacology(Study Group). Maui, HA,
Dec. 13, 1989.
21. Beasley C
TSH response to TRH and differential drug response in psychosis
Founder’s Day Resident Award Paper Presentation, Ohio Psychiatric Association. Toledo, OH,
Apr. 23, 1988.
22. Beasley C
Medication response subtyping of psychoses and neuroendocrine correlates
Indiana University Psychiatric Research Institute Seminar. Indianapolis, IN, Nov. 5, 1987.
23. Beasley C
Serotonin uptake inhibitors in psychiatry
Annual Convention of the Central Neuropsychiatric Association. Indianapolis, IN, Oct. 10, 1987.

34
24. Beasley C
TSH response to TRH and medication response subtypes of psychoses
Maurice Levine Essay Award Presentation, Cincinnati Psychiatric Society. Cincinnati, OH, Apr.
15, 1987.
25. Garver D, Beasley C
Heterogeneity of neuroleptic response in psychosis: implications for subtyping
Psychiatric Research Society Annual Meeting. Tampa, FL, Apr. 4, 1987.
26. Beasley C, Garver D
The heterogeneity of schizophrenic illness(es)
Annual Meeting & Scientific Symposium, Mental Health Association in Ohio. Columbus, OH, Oct.
10, 1986.
27. Beasley C
The acquisition of procedural knowledge: some linguistic examples
University of Kentucky Linguistics Circle. Lexington, KY, Apr. 9, 1980.

Resume-CV 1_May_2015

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (10)

Ähnlich wie Resume-CV 1_May_2015

Ähnlich wie Resume-CV 1_May_2015 (20)

Resume-CV 1_May_2015